TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36056918

Group type: EXPERIMENTAL
Intervention: Placement of dietary diversity questions earlier in the interview
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placement of dietary diversity questions later in the interview
Number of subjects: 0
Study: 34858651

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE), three 40‐min sessions per week for 12 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (non‐exercise group)
Number of subjects: 91
Study: 35127941

Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 32559716

Group type: EXPERIMENTAL
Intervention: digital CBTI
Number of subjects: 91

Group type: COMPARATOR
Intervention: digital sleep education control
Number of subjects: 91
Study: 34505954

Group type: EXPERIMENTAL
Intervention: Magmaris stent
Number of subjects: 50

Group type: COMPARATOR
Intervention: Xience stent
Number of subjects: 50
Study: 33913639

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g)
Number of subjects: 4431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4431
Study: 33979366

Group type: EXPERIMENTAL
Intervention: Linear growth (length for age z score, LAZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulation at home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of diarrhoeal episodes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight for height z scores (WHZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Birth order
Number of subjects: 0
Study: 36096333

Group type: EXPERIMENTAL
Intervention: Mailed self-sampling kit
Number of subjects: 93

Group type: COMPARATOR
Intervention: Clinic screening
Number of subjects: 93
Study: 33845034

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks until disease progression or unacceptable toxicity
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin
Number of subjects: 102
Study: 36113394

Group type: EXPERIMENTAL
Intervention: Sertraline or interpersonal psychotherapy for 14 weeks (T2)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Treatment received (Sertraline or interpersonal psychotherapy)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (female controls)
Number of subjects: 58
Study: 35016413

Group type: EXPERIMENTAL
Intervention: Nursing intervention including a whole‐process escort playing a relative role combined with mind mapping
Number of subjects: 256

Group type: COMPARATOR
Intervention: Routine nursing intervention (Control)
Number of subjects: 256
Study: 33258790

Group type: EXPERIMENTAL
Intervention: myCompass (eMH program)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Healthy Lifestyles (attention control)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Both groups (myCompass and Healthy Lifestyles)
Number of subjects: 780
Study: 33964979

Group type: EXPERIMENTAL
Intervention: Online reciprocal imitation training (RIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 20
Study: 32695652

Group type: EXPERIMENTAL
Intervention: Tai Chi Qigong (TCQ)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (meeting class once a week for 12 weeks)
Number of subjects: 50
Study: 33500235

Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ureteroscopy
Number of subjects: 60
Study: 34212560

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine plus intravenous remifentanil (DEX-REMI group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous remifentanil only (REM group)
Number of subjects: 40
Study: 35289848

Group type: EXPERIMENTAL
Intervention: Karydakis flap surgery
Number of subjects: 125

Group type: COMPARATOR
Intervention: Excision and suture in the midline
Number of subjects: 125
Study: 33664086

Group type: EXPERIMENTAL
Intervention: Enzalutamide for 3 months
Number of subjects: 38
Study: 33187978

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 131

Group type: COMPARATOR
Intervention: Interferon-α2
Number of subjects: 131
Study: 35350988

Group type: EXPERIMENTAL
Intervention: Levosimendan + Shenfu injection (SFI)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Levosimendan
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Levosimendan + SFI
Number of subjects: 101
Study: 33823265

Group type: EXPERIMENTAL
Intervention: Lower extremity intermittent negative pressure (INP) of -40 mm Hg for one hour twice daily for 24 weeks
Number of subjects: 10
Study: 32347365

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group without IORT
Number of subjects: 38
Study: 35573387

Group type: EXPERIMENTAL
Intervention: Integrated intervention combining CBT4CBT and Recovery Coaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study: 33871363

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (L. plantarum PBS067, L. reuteri PBS072, L. rhamnosus LRH020) for 56 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 56 days
Number of subjects: 80
Study: 36040071

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B gel (LAmB gel) for 28 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo gel for 28 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B gel (LAmB gel) for 56 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All patients at 56 days
Number of subjects: 13
Study: 33540112

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied offline over right DLPFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied offline over left PPC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied offline over right PPC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied offline over left DLPFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online tDCS (various loci)
Number of subjects: 0
Study: 33000366

Group type: EXPERIMENTAL
Intervention: intermittent theta-burst stimulation (iTBS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 28
Study: 32707917

Group type: EXPERIMENTAL
Intervention: 12 h fasting duration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 14 h fasting duration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 16 h fasting duration
Number of subjects: 24
Study: 36071664

Group type: EXPERIMENTAL
Intervention: Tablet for multimodal learning
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nurse explanation on home self‐injection of enoxaparin sodium (Control)
Number of subjects: 80
Study: 32889626

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 40

Group type: COMPARATOR
Intervention: sEMG
Number of subjects: 40
Study: 32864755

Group type: EXPERIMENTAL
Intervention: Body imagery rescripting
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: General imagery rescripting
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study: 34554879

Group type: EXPERIMENTAL
Intervention: Chronic pain acceptance
Number of subjects: 187
Study: 33787151

Group type: EXPERIMENTAL
Intervention: Yangxue Qingnao Granules combined with conventional anti-hypertensive agents
Number of subjects: 4532
Study: 34862359

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) applied to the injured left-hemispheric cortex for 1-3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment (Tx0) for 3 weeks
Number of subjects: 0
Study: 33054008

Group type: EXPERIMENTAL
Intervention: Traditional conservative therapy and different wavelengths laser therapy (LT) course
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Traditional conservative therapy and intravenous laser blood irradiation (ILBI) (λ - 635 nm)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional conservative therapy only
Number of subjects: 102
Study: 36289532

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7 + 3
Number of subjects: 0
Study: 34839884

Group type: EXPERIMENTAL
Intervention: Hemodynamic resuscitation with Ringer lactate (20mL·kg‐1) and norepinephrine initiated 3h after sepsis induction
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (SHAM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sepsis group without hemodynamic resuscitation (ETX‐NR)
Number of subjects: 18
Study: 36388664

Group type: COMPARATOR
Intervention: Group B (FiO2 =0.6, PEEP =5 cmH2O)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group D (FiO2 =1.0, PEEP =10 cmH2O)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group A (FiO2 =0.6, PEEP =0)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group C (FiO2 =1.0, PEEP =8 cmH2O)
Number of subjects: 120
Study: 32028927

Group type: EXPERIMENTAL
Intervention: My Joint Pain website (users)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Control group (non-users)
Number of subjects: 277
Study: 35710594

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Established antihypertensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change to a regimen compatible with pregnancy
Number of subjects: 0
Study: 33221789

Group type: EXPERIMENTAL
Intervention: Knowledge and attitudes about cancer and its risk factors
Number of subjects: 1200
Study: 35649128

Group type: EXPERIMENTAL
Intervention: Rigid wrist-hand orthosis worn ≥6 hours per night for 3 years
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (usual multidisciplinary care)
Number of subjects: 74
Study: 35730245

Group type: EXPERIMENTAL
Intervention: EsoduoⓇ (esomeprazole 20 mg with sodium bicarbonate 800 mg)
Number of subjects: 379

Group type: COMPARATOR
Intervention: NexiumⓇ (esomeprazole 20 mg)
Number of subjects: 379
Study: 34124929

Group type: EXPERIMENTAL
Intervention: Individual Cognitive Processing Therapy (CPT)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy (CPT)
Number of subjects: 254
Study: 32414888

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (post‐tetanic count 1 or 2)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Moderate neuromuscular block (train‐of‐four 1 or 2)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Number of subjects: 58

Group type: COMPARATOR
Intervention: Moderate neuromuscular block
Number of subjects: 58
Study: 35417957

Group type: EXPERIMENTAL
Intervention: Mild hemodilution (hematocrit maintained >25%)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Moderate hemodilution (hematocrit maintained within 21-25%)
Number of subjects: 186
Study: 33952531

Group type: EXPERIMENTAL
Intervention: Repeated damage from induced earthquakes
Number of subjects: 3934
Study: 32198939

Group type: EXPERIMENTAL
Intervention: Branebrutinib (0.3-30 mg for SAD; 0.3-10 mg for JMAD)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Branebrutinib (daily for 14 days in MAD)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Branebrutinib (single 10 mg dose)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 35869266

Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ruxolitinib then momelotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best available therapy then momelotinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline transfusion independence (TI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Week 24 TI response in JAKi-naïve, momelotinib-randomized patients
Number of subjects: 0
Study: 32158202

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) - 9-week program, twice a week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (CG) - attended disease lectures
Number of subjects: 40
Study: 36116766

Group type: EXPERIMENTAL
Intervention: QST-derived sensory phenotype 'sensory loss'
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: QST-derived sensory phenotype 'mechanical hyperalgesia'
Number of subjects: 133
Study: 34397698

Group type: EXPERIMENTAL
Intervention: Combined Naikan therapy (NT) and Morita therapy (MT) for 7 consecutive weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Normal medical treatments without NT and MT
Number of subjects: 130
Study: 32776533

Group type: EXPERIMENTAL
Intervention: 0.01% atropine with orthokeratology (AOK)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ortho-k only (OK)
Number of subjects: 59
Study: 36173238

Group type: EXPERIMENTAL
Intervention: Insulin-only configuration of the iLet® bionic pancreas (BP)
Number of subjects: 90
Study: 32515894

Group type: EXPERIMENTAL
Intervention: GreenLight HPS laser 120 W (PVP)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Diode laser 300 W (CVP)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 153
Study: 32502564

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) sessions (3 sessions of 20 minutes each over 3 consecutive days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) sessions (group 1, n=10)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control condition (regular rehabilitation practice over a week)
Number of subjects: 24
Study: 35969979

Group type: EXPERIMENTAL
Intervention: Video interviews
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person interviews
Number of subjects: 0
Study: 33238718

Group type: EXPERIMENTAL
Intervention: Yoga-informed intervention program (The Incredible Explorers, 6-week program)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (waiting to receive the intervention)
Number of subjects: 61
Study: 32585997

Group type: EXPERIMENTAL
Intervention: Multispecies probiotics
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 35337193

Group type: EXPERIMENTAL
Intervention: Development and Well-Being Assessment (DAWBA) as an adjunct to referral letters
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard referral letters without DAWBA
Number of subjects: 160
Study: 32418785

Group type: EXPERIMENTAL
Intervention: MRI radiomics based on enhanced T1WI images
Number of subjects: 98
Study: 35805311

Group type: EXPERIMENTAL
Intervention: Partly structured activity group (N = 62)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Free-play group (N = 43)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (N = 36)
Number of subjects: 145
Study: 35486044

Group type: EXPERIMENTAL
Intervention: Closure without balloon sizing
Number of subjects: 381

Group type: COMPARATOR
Intervention: Closure using balloon sizing
Number of subjects: 381
Study: 616714877

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 35461285

Group type: EXPERIMENTAL
Intervention: Antisecretory factor (Salovum®) as a food supplement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32659919

Group type: EXPERIMENTAL
Intervention: Gluten-Free meal (GF)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Whole Food meal (WF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Processed Food meal (PF)
Number of subjects: 11
Study: 33596852

Group type: EXPERIMENTAL
Intervention: Cranberry beverage consumed daily for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cranberry beverage
Number of subjects: 0
Study: 33047325

Group type: EXPERIMENTAL
Intervention: Coping with and Caring for Infants with Special Needs (COPCA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard infant physiotherapy
Number of subjects: 16
Study: 32037483

Group type: EXPERIMENTAL
Intervention: Peer‐mediated intervention (PMI) for children with ASD
Number of subjects: 65
Study: 35013866

Group type: EXPERIMENTAL
Intervention: Omega-3 and omega-6 fatty acid supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32513257

Group type: EXPERIMENTAL
Intervention: Topical Timoptic-XE® (timolol maleate ophthalmic gel forming solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) plus hydrogel (placebo)
Number of subjects: 0
Study: 35340222

Group type: EXPERIMENTAL
Intervention: Radiomics signatures based on preoperative F-FDG PET/CT
Number of subjects: 120
Study: 33840651

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions focusing on exercise, nutrition, social participation, and improvement of mental health.
Number of subjects: 9754
Study: 33576591

Group type: EXPERIMENTAL
Intervention: Professional burnout syndrome
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 378
Study: 36202911

Group type: EXPERIMENTAL
Intervention: Gambling-like rewards (loot box)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Fixed rewards
Number of subjects: 153

Group type: COMPARATOR
Intervention: No rewards
Number of subjects: 153
Study: 33691504

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Best medical management (control)
Number of subjects: 315
Study: 33001232

Group type: EXPERIMENTAL
Intervention: 30 mg/day of pioglitazone for 16 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 41
Study: 33247012

Group type: EXPERIMENTAL
Intervention: 99DOTS-based treatment supervision
Number of subjects: 1890

Group type: COMPARATOR
Intervention: Routine care (DOT)
Number of subjects: 1890
Study: 34375990

Group type: EXPERIMENTAL
Intervention: Loaded Inter-set Stretching (ISS) for 30 seconds at 15% of working load
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional Resistance Training (TR)
Number of subjects: 26
Study: 34107933

Group type: EXPERIMENTAL
Intervention: Oral rehabilitation procedures
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no oral rehabilitation during the study period)
Number of subjects: 80
Study: 35088531

Group type: EXPERIMENTAL
Intervention: Bandage fixation method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endotracheal tube holder fixation
Number of subjects: 60
Study: 34277476

Group type: EXPERIMENTAL
Intervention: M+P (Miltefosine 50 mg BID and Pentoxifylline 400 mg TID)
Number of subjects: 43

Group type: COMPARATOR
Intervention: A+P (Antimonials 20 mg Sb+V/kg/day IV and Pentoxifylline 400 mg TID)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CL patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Treatment comparison (M+P vs A+P)
Number of subjects: 43
Study: 36112655

Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg Se methionine
Number of subjects: 300

Group type: COMPARATOR
Intervention: 0.6, 0.3, and 0.0 mg/kg Se methionine
Number of subjects: 300
Study: 33631890

Group type: EXPERIMENTAL
Intervention: Deep learning method for pancreatic segmentation on CT in arterial phase
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Deep learning method for pancreatic segmentation on CT in venous phase
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Groups with fat gaps in venous phase
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Groups without fat gaps in venous phase
Number of subjects: 218
Study: 32695229

Group type: EXPERIMENTAL
Intervention: Resveratrol 100 mg capsule daily for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33471452

Group type: EXPERIMENTAL
Intervention: Lower oxygenation target (Pao2 of 60 mm Hg)
Number of subjects: 2928

Group type: COMPARATOR
Intervention: Higher oxygenation target (Pao2 of 90 mm Hg)
Number of subjects: 2928
Study: 32100493

Group type: EXPERIMENTAL
Intervention: Acupuncture at the affected side's Tunyan, Fayin and Zhifanliu (Extra)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Acupuncture at both sides' Tunyan, Fayin and Zhifanliu
Number of subjects: 66
Study: 32645251

Group type: EXPERIMENTAL
Intervention: 1% Sandalore® solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (identically smelling, but non-OR2AT4 activating sandalwood oil)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patient self-assessment
Number of subjects: 60
Study: 32388511

Group type: EXPERIMENTAL
Intervention: Nonsynchronized nasal intermittent positive pressure ventilation (NS‐NIPPV)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 220
Study: 35401778

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UL)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 104
Study: 33243284

Group type: EXPERIMENTAL
Intervention: M. communis preparation in addition to conventional therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 36303227

Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (ECPR)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Conventional advanced cardiac life support (ACLS)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Prehospital return of spontaneous circulation (ROSC)
Number of subjects: 256
Study: 32649736

Group type: EXPERIMENTAL
Intervention: GLS4 (120 mg) and ritonavir (100 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GLS4 (240 mg) and ritonavir (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Entecavir treatment
Number of subjects: 24
Study: 34856290

Group type: EXPERIMENTAL
Intervention: Oxygen-enriched air (FiO2 0.50)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ambient air (FiO2 0.21)
Number of subjects: 7
Study: 32163927

Group type: EXPERIMENTAL
Intervention: Interrupted sitting (sitting for 3 hours with walking for 3 minutes every 30 minutes)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Continuous sitting (sitting for 3 hours)
Number of subjects: 61
Study: 36122259

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection into coracohumeral ligament (CHL) and inferior glenohumeral capsule (IGHC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Corticosteroid injection into posterior glenohumeral recess (PGHR)
Number of subjects: 120
Study: 32567391

Group type: EXPERIMENTAL
Intervention: Patient phone calls and virtual wound checks within 72 hours of discharge
Number of subjects: 91

Group type: COMPARATOR
Intervention: Historical control data
Number of subjects: 91
Study: 34429340

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (240 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54